Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new‐onset diabetes mellitus and glucose metabolism: A systematic review and meta‐analysis

Aims To investigate the effect of two clinically applied proprotein convertase subtilisin/kexin type 9 monoclonal antibodies (PCSK9‐mAbs) on glycaemia and new‐onset diabetes mellitus (NODM). Materials and Methods PubMed, MEDLINE, Embase, Cochrane databases and ClinicalTrials.gov websites were system...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes, obesity & metabolism obesity & metabolism, 2018-06, Vol.20 (6), p.1391-1398
Hauptverfasser:	Cao, Ye‐Xuan, Liu, Hui‐Hui, Dong, Qiu‐Ting, Li, Sha, Li, Jian‐Jun
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal - therapeutic use Anticholesteremic Agents - therapeutic use Blood glucose Blood Glucose - metabolism Body Mass Index Cholesterol Cholesterol, LDL - metabolism Diabetes Diabetes mellitus Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Evidence-based medicine Fasting - blood Female Glucose Glucose metabolism Glycated Hemoglobin A - metabolism Hemoglobin Homeostasis Humans Hypercholesterolemia - blood Hypercholesterolemia - drug therapy Hypoglycemic Agents - therapeutic use Kexin Low density lipoprotein Male Meta-analysis Middle Aged Monoclonal antibodies new‐onset diabetes mellitus PCSk9‐mAb Proprotein Convertase 9 - immunology Proprotein convertases Randomized Controlled Trials as Topic Sensitivity analysis Subtilisin Systematic review
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!